Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Maria Gonzalez-Cao"'
Autor:
James L Gulley, Elad Sharon, Julius Strauss, Steven P Fling, Anna Wright, Teresa Moran, Kathryn Lurain, Ramya Ramaswami, Thomas S Uldrick, Robert Yarchoan, Maria Gonzalez-Cao, Javier Martinez-Picado, Thomas A Odeny
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background The Food and Drug Administration recommends that people living with HIV (PWH) with a CD4+ T cell count (CD4) ≥350 cells/µL may be eligible for any cancer clinical trial, but there is reluctance to enter patients with lower CD4 counts in
Externí odkaz:
https://doaj.org/article/040ee9ed4fc648b5b5356b0d33884972
Autor:
Enriqueta Felip, Mario Sznol, Harriet Kluger, Erin Filbert, Valentina Boni, Montaser Shaheen, Nicholas Iannotti, Delvys Rodriguez-Abreu, Maria Gonzalez-Cao, Alfonso Berrocal, Ralph Hauke, Lynn Schuchter, Gerald Linette, Sarah Weiss, Miguel-Ángel Berciano-Guerrero, Ana Maria Arance, Apar Kishor Ganti
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/486cee47556042ac976f547e0220656d
Autor:
José Luis Manzano, Ivan Marquez-Rodas, Cristina Carrera, Mario Mandala, Eva Muñoz-Couselo, Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, Carolina Ortiz, Roger Paredes, Daniel Podzamczer, Jose Molto, Boris Revollo, Lourdes Mateu, Sara Fancelli, Enrique Espinosa, Bonaventura Clotet, Javier Martinez-Picado, Pablo Cerezuela, Ainara Soria, Alfonso Berrocal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumo
Externí odkaz:
https://doaj.org/article/9b4da5993e134c378f9c571d2ea5242c
Autor:
Richard E. Kast, Alex Alfieri, Hazem I. Assi, Terry C. Burns, Ashraf M. Elyamany, Maria Gonzalez-Cao, Georg Karpel-Massler, Christine Marosi, Michael E. Salacz, Iacopo Sardi, Pieter Van Vlierberghe, Mohamed S. Zaghloul, Marc-Eric Halatsch
Publikováno v:
Cancers, Vol 14, Iss 10, p 2563 (2022)
In part one of this two-part paper, we present eight principles that we believe must be considered for more effective treatment of the currently incurable cancers. These are addressed by multidrug adjunctive cancer treatment (MDACT), which uses multi
Externí odkaz:
https://doaj.org/article/f689d38ad7e541139d612f74198ba3a5
Autor:
Maria Gonzalez-Cao, Niki Karachaliou, Mariacarmela Santarpia, Santiago Viteri, Andreas Meyerhans, Rafael Rosell
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
A coordinated action of innate and adaptive immune responses is required to efficiently combat a microbial infection. It has now become clear that cancer therapies also largely benefit when both arms of the immune response are engaged. In this review
Externí odkaz:
https://doaj.org/article/9cc0451683384039be5a94a3d46a0cf8
Autor:
Niki Karachaliou, Maria Gonzalez-Cao, Guillermo Crespo, Ana Drozdowskyj, Erika Aldeguer, Ana Gimenez-Capitan, Cristina Teixido, Miguel Angel Molina-Vila, Santiago Viteri, Maria De Los Llanos Gil, Salvador Martin Algarra, Elisabeth Perez-Ruiz, Ivan Marquez-Rodas, Delvys Rodriguez-Abreu, Remedios Blanco, Teresa Puertolas, Maria Angeles Royo, Rafael Rosell
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression of IFNG, the gene encoding IFN-γ, is associated with clinical response to
Externí odkaz:
https://doaj.org/article/8ac2c8fef28b486789e2a6c0357c1a10
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/a71637a762b04bf3be25a17680e25ef7
Autor:
Rafael Rosell, Anisha Jain, Jordi Codony-Servat, Eloisa Jantus-Lewintre, Blake Morrison, Jordi Barretina Ginesta, María González-Cao
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 7, Pp 500-518 (2023)
Lung oncogenesis relies on intracellular cysteine to overcome oxidative stress. Several tumor types, including non-small cell lung cancer (NSCLC), upregulate the system xc- cystine/glutamate antiporter (xCT) through overexpression of the cystine tran
Externí odkaz:
https://doaj.org/article/c75dc006ae7f4f98914e3994f585c6bd
Autor:
Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez, Rocío López-Vacas, Virtudes Soriano, Fernando Garicano, M. José Lecumberri, María Rodríguez de la Borbolla, Margarita Majem, Elisabeth Pérez-Ruiz, María González-Cao, Juana Oramas, Alejandra Magdaleno, Joaquín Fra, Alfonso Martín-Carnicero, Mónica Corral, Teresa Puértolas, Ricardo Ramos-Ruiz, Antje Dittmann, Paolo Nanni, Juan Ángel Fresno Vara, Enrique Espinosa
Publikováno v:
Cancers, Vol 15, Iss 17, p 4407 (2023)
Immunotherapy improves the survival of patients with advanced melanoma, 40% of whom become long-term responders. However, not all patients respond to immunotherapy. Further knowledge of the processes involved in the response and resistance to immunot
Externí odkaz:
https://doaj.org/article/6da6bdb748d84ad08bfecc4b64fa7420
Autor:
Manuel Sánchez-Prieto, Francesc Fargas, Francesc Tresserra, María González-Cao, Sonia Baulies, Rafael Fábregas
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1144-1151 (2021)
Vulvar malignant melanoma is the second most common subtype of vulvar cancer, accounting for 5–10% of all vulvar cancers. The prognosis is still very poor, although some advances have been achieved in the last years. One of the most significant cha
Externí odkaz:
https://doaj.org/article/429026ae82684c78af9a8a59dfd15596